CEO
Zhisheng Chen
Employees
1,830
Industry
Testing Laboratories
wuxi biologics provides an open-access, integrated technology platform for biologics drug development. we are the only true service platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. our single-source approach to biologics development saves our clients critical time and money. see below how our experience, capacities and quality make us a world leading (cdmo). experience wuxi biologics’ leadership team consists of industry experts with 15-20 years of experience in biological drug development in the u.s./eu. while at wuxi this team has contributed to 1 bla and 66 worldwide inds in just 3 years! expertise wuxi biologics has over 170+ returnees from large pharma and small biotechs in the u.s./eu. these scientists cover all facets of drug development from discovery to manufacture of final drug product. capacity and capabilities we have strong technical capabilities and an open-access
Loading...
Open
3.66
Mkt cap
7.6B
Volume
5.4K
High
3.67
P/E Ratio
21.59
52-wk high
11.73
Low
3.64
Div yield
N/A
52-wk low
2.58
Portfolio Pulse from
November 14, 2024 | 4:15 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.